Showing results (21-30 of 92) with videos related to
Sort By:
Pageof 10
Journal of Gastrointestinal Oncology|March 17, 2020
Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemiaJane E Rogers, Jonathan D Mizrahi, Rachna T Shroff, et al.World Journal of Gastrointestinal Oncology|October 31, 2019
Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolismAlejandro Recio-Boiles, Sumana Veeravelli, Jessica Vondrak, et al.Medical Sciences (Basel, Switzerland)|August 24, 2018
Improving Blood Transfusion Practices in a Community Hospital Setting: Our Experience with Real-Time Clinical Decision SupportMuhammad Sardar, Muhammad Azharuddin, Ananta Subedi, et al.Journal of Hematology & Oncology|May 31, 2018
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinomaReham Abdel-Wahab, Gauri R Varadhachary, Priya R Bhosale, et al.Cancer|November 19, 2016
Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 studyPat Gulhati, Kanwal Raghav, Rachna T Shroff, et al.BMC Cancer|July 16, 2010
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studiesMilind M Javle, Rachna T Shroff, Henry Xiong, et al.Cureus|November 4, 2025
Incidental Atrial Myxoma in the Shadow of COVID-19: Coincidence or an Emerging Pattern?Bilal Rashid, Isfandyar Baig, Muhammad Dawar Feroze, et al.SAGE Open Medical Case Reports|March 13, 2019
Progressive left lower extremity weakness in a patient with multiple myeloma: A diagnostic dilemmaMuhammad Sardar, Nasreen Shaikh, Saad Ullah Malik, et al.Cancer|August 7, 2016
Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistanceDaniel H Ahn, Milind Javle, Chul W Ahn, et al.British Journal of Cancer|April 26, 2017
The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinomaRachna T Shroff, Mark Yarchoan, Ashley O'Connor, et al.Pageof 10